C3AR1 is upregulated in AD and its selective targeting expected to modulate inflammation without adversely affecting other critical complement processes like phagocytosis and clearance (C3b) and the membrane attack complex (C5b/MAC). This evidence concerns the gene C3 and Alzheimer disease.